Skip to main content

Sofinnova Crossover II SLP

Position in COAG — Hemab Therapeutics Holdings, Inc.

CIK 2086593

All Filings in COAG

Export CSV
1 filing row on record
Report Date Value (USD) Shares
2026-06-30 $92,236,816 2,511,212